OTLK Up More Than 300% in 3 Months: Here's What You Should Know

Shares of Outlook Therapeutics have skyrocketed 311.8% in the past three months compared with the industry’s increase of 6.9%.

Image Source: Zacks Investment Research

Last month, the FDA approved Lytenava for the treatment of neovascular age-related macular degeneration (nAMD), commonly known as wet AMD. The approval, which came ahead of schedule, marked a significant milestone for the company, with the prospect of bringing the drug to the U.S. market.

In June 2026, the FDA accepted the resubmitted biologics license application (BLA) for Lytenava in wet AMD.

The approval followed the FDA’s acceptance of the resubmitted BLA, after the company resolved the issues raised in the FDA’s complete response letter in December 2025. Outlook Therapeutics expects to launch Lytenava in the United States by the end of 2026, making the upcoming commercial launch an important potential catalyst for the stock.

As Outlook Therapeutics prepares to report its third-quarter fiscal 2026 results later this week, investors are likely to focus on the company’s U.S. launch plans for Lytenava. A successful launch could improve investor confidence in Lytenava’s revenue potential and provide further upside to OTLK shares.

More on OTLK’s Lytenava Rollout in Europe

Lytenava has been commercialized across the European Union and the United Kingdom since 2024. Outlook Therapeutics commenced commercial launch of Lytenava in Germany and the United Kingdom as a treatment for wet AMD.

Over the past few quarters, Outlook Therapeutics has generated modest revenues from Lytenava sales in ex-U.S. markets. However, European product sales are likely to improve sequentially, as Lytenava is already launched in select markets and management previously noted a recovery in unit sales following an initial slowdown.

Now that Lytenava is approved by the FDA, it should hold stronger commercial momentum ahead of the planned U.S. launch.

It can be inferred that the company will be more focused on the U.S. commercial rollout, inventory availability and reimbursement progress of Lytenava.

Outlook Therapeutics’ recent development with Lytenava indicates long-term growth potential.

OTLK’s Zacks Rank & Stocks to Consider

Outlook Therapeutics currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Harmony Biosciences HRMY, Repligen RGEN and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have risen from $3.20 to $3.62, while estimates for 2027 have increased from $3.64 to $4.07 during the same time. HRMY shares have gained 2.6% year to date.

Harmony Biosciences’ earnings missed estimates in three of the trailing four quarters and beat on the remaining occasion, delivering an average negative surprise of 13.97%.

Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares failed to deliver any returns year to date.

Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.

Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 161.3% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research